Ken Griffin’s Citadel bets £300mn against drugmaker GSK
Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.
Citadel Gives Rare Glimpse of $57 Billion Gains From Its Largest Funds
Citadel offered a rare glimpse under the hood of its multistrategy funds during a lucrative period for the most profitable ...
Portfolio managers turned consultants and podcasters are demystifying what it's like to work at big-name hedge funds like Citadel or Point72
Multistrategy hedge funds are bigger than ever. Some who have worked for the biggest brands are now advising others on how to ...
PRESS: Ken Griffin's Citadel bets GBP300 million against GSK - FT
(Alliance News) - Hedge fund Citadel has made a GBP305 million bet against pharmaceuticals firm GSK PLC, the biggest short position against the company in more than a decade, according to the ...
Ken Griffin's mutistrategy hedge fund at Citadel rose 1.4% in volatile January
Citadel's multistrategy flagship Wellington fund climbed 1.4% in January, following a 15.1% gain in 2024, according to the ...
GSK shares shorted by leading U.S. hedge fund, The Times reports
The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s ...
Hedge Funds Are Pocketing Much of Their Clients’ Gains With ‘No Limit’ Fees
A Bloomberg analysis of the major hedge funds’ regulatory filings shows their passthrough fees have exploded in recent years.
Citadel downsizing to River North in reshuffle with Bain & Co
Ken Griffin’s hedge fund is taking a fraction of the space in its exit from Citadel Center; TPG Angelo Gordon negotiating ...
Business Times7d
Citadel gives rare glimpse of US$57 billion gains from its largest funds
CITADEL offered a rare glimpse under the hood of its multistrategy funds during a lucrative period for the most profitable ...